| Ytd | -33.49% | |
| 1y | 11.13% |
| Open | 3.59 | Prev Close | 3.55 | Low | 3.51 | High | 3.65 | Mkt Cap | 209.20M |
| Vol | 79.38K | Avg Vol | 585.78K | EPS | -1.36 | P/E | N/A | Forward P/E | -1.61 |
| Beta | 1.49 | Short Ratio | 14.46 | Inst. Own | 51.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 3.95 | 200-d Avg | 4.99 | 1yr Est | 26.40 |
TARA News
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the a
$100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD C
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperfor
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002
Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the
JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the ana
HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics (NASDAQ:TARA) with
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transfor
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.37) per share which missed the a
JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Ove
Protara Therapeutics (TARA) shares down after release of interim results for TARA-002 treatment of N
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse event
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA)
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapi
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patien
Piper Sandler analyst Kelsey Goodwin initiates coverage on Protara Therapeutics (NASDAQ:TARA) wit
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapi
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therap
Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara"), a clinical-stage company developing tr
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA)
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therap
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therap
TARA-002, a cell-based therapy by Protara Therapeutics, shows promising results in treating lymphati
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA)
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therap
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapi
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therap
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the ana
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.35) per share which beat the ana
Jones Trading analyst Soumit Roy initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.29) per share which beat the ana
HC Wainwright & Co. analyst Andres Maldonado reiterates Protara Therapeutics (NASDAQ:TARA) wi
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete res
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-st
